42. Williams CR, Sykes JE, Mehl M, et al. In vitro effects of the active metabolite of leflunomide, A77 1726, on feline herpesvirus-1.
Am J Vet Res 2007;68(9):1010-1015.
43. Hanna FY. Disease modifying treatment for feline rheumatoid arthritis. Vet Comp Orthop Traumatol 2005;18(2):94-99.
44. Colopy SA, Baker TA, Muir P. Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008).
J Am Vet Med Assoc 2010;236(3):312-318.
45. Gregory CR, Stewart A, Sturges B, et al. Leflunomide effectively treats naturally occurring immune-mediated and inflammatory
diseases of dogs that are unresponsive to conventional therapy. Transplant Proc 1998;30(8):4143-4148.
46. Bianco D, Hardy RM. Treatment of Evans' syndrome with human intravenous immunoglobulin and leflunomide in a diabetic dog.
J Am Anim Hosp Assoc 2009;45(3):147-150.
47. Mason N, Duval D, Shofer FS, et al. Cyclophosphamide exerts no beneficial effect over prednisone alone in the initial treatment
of acute immune-mediated hemolytic anemia in dogs: a randomized controlled clinical trial. J Vet Intern Med 2003;17(2):206-212.
48. Burgess K, Moore A, Rand W, et al. Treatment of immune-mediated hemolytic anemia in dogs with cyclophosphamide. J Vet Intern Med 2000;14(4):456-462.
49. Willard MD. Feline inflammatory bowel disease: a review. J Feline Med Surg 1999;1(3):155-164.
50. Allenspach K, Rufenacht S, Sauter S, et al. Pharmacokinetics and clinical efficacy of cyclosporine treatment of dogs with
steroid-refractory inflammatory bowel disease. J Vet Intern Med 2006;20(2):239-244.
|
Featuring Information from:
